» Articles » PMID: 37593531

Harm Reduction: A Missing Piece to the Holistic Care of Patients Who Inject Drugs

Overview
Date 2023 Aug 18
PMID 37593531
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The rise in injection drug use (IDU) has led to an increase in drug-related infections. Harm reduction is an important strategy for preventing infections among people who inject drugs (PWID). We attempted to evaluate the harm reduction counseling that infectious diseases physicians provide to PWID presenting with infections.

Methods: An electronic survey was distributed to physician members of the Emerging Infections Network to inquire about practices used when caring for patients with IDU-related infections.

Results: In total, 534 ID physicians responded to the survey. Of those, 375 (70%) reported routinely caring for PWID. Most respondents report screening for human immunodeficiency virus (HIV) and viral hepatitis (98%) and discussing the risk of these infections (87%); 63% prescribe immunization against viral hepatitis, and 45% discuss HIV preexposure prophylaxis (PrEP). However, 55% of respondents (n = 205) reported not counseling patients on safer injection strategies. Common reasons for not counseling included limited time and a desire to emphasize antibiotic therapy/medical issues (62%), lack of training (55%), and believing that it would be better addressed by other services (47%). Among respondents who reported counseling PWID, most recommended abstinence from IDU (72%), handwashing and skin cleansing before injection (62%), and safe disposal of needles/drug equipment used before admission (54%).

Conclusions: Almost all ID physicians report screening PWID for HIV and viral hepatitis and discussing the risks of these infections. Despite frequently encountering PWID, fewer than half of ID physicians provide safer injection advice. Opportunities exist to standardize harm reduction education, emphasizing safer injection practices in conjunction with other strategies to prevent infections (eg, HIV PrEP or hepatitis A virus/hepatitis B virus vaccination).

Citing Articles

Infectious Diseases Fellowship Training in Caring for People Who Use Drugs: A National Assessment of an Emerging Training Need.

Vasishta S, Jawa R, Kurz S, Nolan N Open Forum Infect Dis. 2024; 11(10):ofae544.

PMID: 39411220 PMC: 11474980. DOI: 10.1093/ofid/ofae544.


Drug preparation, injection-related infections, and harm reduction practices among a national sample of individuals entering treatment for opioid use disorder.

Marks L, Durkin M, Ayres K, Ellis M Harm Reduct J. 2024; 21(1):16.

PMID: 38243269 PMC: 10799462. DOI: 10.1186/s12954-024-00939-6.

References
1.
Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C . Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019; 321(22):2214-2230. DOI: 10.1001/jama.2019.2591. View

2.
Foster M, Hofmeister M, Yin S, Montgomery M, Weng M, Eckert M . Widespread Hepatitis A Outbreaks Associated with Person-to-Person Transmission - United States, 2016-2020. MMWR Morb Mortal Wkly Rep. 2022; 71(39):1229-1234. PMC: 9533732. DOI: 10.15585/mmwr.mm7139a1. View

3.
Ronan M, Herzig S . Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12. Health Aff (Millwood). 2016; 35(5):832-7. PMC: 5240777. DOI: 10.1377/hlthaff.2015.1424. View

4.
Ryerson A, Schillie S, Barker L, Kupronis B, Wester C . Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018. MMWR Morb Mortal Wkly Rep. 2020; 69(14):399-404. PMC: 7147907. DOI: 10.15585/mmwr.mm6914a2. View

5.
Fanucchi L, Walsh S, Thornton A, Nuzzo P, Lofwall M . Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections. Clin Infect Dis. 2019; 70(6):1226-1229. PMC: 7931831. DOI: 10.1093/cid/ciz654. View